PARSIPPANY, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company, today announced that management will participate in the following investor events:
2023 Mizuho Medical Device and Healthcare Services Summit
2023 MedTech Madness Annual West Coast Bus Tour
About embecta
embecta is a global diabetes care company that is leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, Instagram and Twitter.
Contacts:
| Media | Investors |
| Christian Glazar | Pravesh Khandelwal |
| Sr. Director, Corporate Communications | VP, Head of Investor Relations |
| 908-821-6922 | 551-264-6547 |
| This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$12.57 |
| Daily Volume: | 0 |
| Market Cap: | US$735.220M |
November 25, 2025 November 17, 2025 August 08, 2025 February 06, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
